Arvind Remedies Limited
Add to watch list to get report alerts
BSE Code:
531823
NSE Code:
ARL
Business Profile
Business Profile
Arvind Remedies (ARVREMED) is engaged in the manufacture, marketing and export of allopathic and ayurvedic pharmaceutical products. Established in 1988 as a private limited company, the company went pubic in April 1996. It is promoted by Arvind Shah, the managing director and chief executive officer.
The company has made significant contribution in cardiology, dermatology, nephrology and diabetes. It manufactures allopathic ethical products like Nimser (anti-inflammatory), Carolox (anti infectives), Vitoxid AO (antioxidant), Artin 250 (anti rheumatic), Dispas DT (anti spasmodic),..etc; branded generic drugs like Alben 400 (anthelmintic), Amoxycillin DT (semi-synthetic), Erythromycin (antibiotic), Racy 500 (antibiotic), ..etc; generic products like trypsin chymotrypsin (acute inflammatory oedema), verapamil (anti hypertensive), ..etc. It also produces ayurvedic products like artin oil, Hygenex, Pankare, Pankare (tablet), Solufat, Sorexil, Stresof, and Utritone.
The company`s state-of-the-art manufacturing facility and research and development lab is located in Kakkalur, Chennai and has been certified with GMP under WHO norms. All products are ISO 9002 certified. The annual capacity of the company is 1.47 million tablets, 421,000 capsules, 2,140 kg ointments and 2,004 liters of liquids.
The company`s Indian client portfolio includes prestigious defence establishments, ESI, CGHS, central and state government institutions, public sector companies, P&T, railways and world bank projects. It exports to Africa, Commonwealth of Independent States and Asian countries. It has commenced registration of products in several countries including Malaysia, Tanzania, Sri Lanka, Ukraine, Nigeria and Nepal.
The registered office is at 190, Poonamallee High Road, Chennai-600084, Tamil Nadu.
Financials
Arvind Remedies registered a 22.05% growth in net profit to Rs 27.79 million for the quarter ended June 2007 from a profit of Rs 22.77 million for the quarter ended June 2006.
Net sales rose 3.16% to Rs 404.72 million for the quarter ended June 2007 from Rs 392.34 million for the quarter ended June 2006.
Total income rose 3.24% to Rs 405.31 million for the quarter ended June 2007 from Rs 392.58 million for the quarter ended June 2006.
The earnings per share (EPS) of the company stood at Rs 0.11 for the quarter ended June 2007.
Recent Developments
01-JUN-06
The company has entered into an agreement with Sri Ramachandra Medical College & Research Institute (SRMC & RI) (Deemed University), Chennai and Department of Science & Technology, Ministry of Science & Technology, Government of India, New Delhi for a project in research and development of Ayurvedic herbal medicine for rheumatoid arthritis. The total project cost is estimated to be around Rs 10.3 million.
Future Plans
The company is coming up with a new manufacturing unit in Haridwar, Uttaranchal, which will have manufacturing wings for all the dosage forms with high tech machinery supported by R&D facility. This unit will measure up to the requirements of US FDA, UK MCA and Australian`s TGA standards.